Delcath Systems Inc. (DCTH)
NASDAQ: DCTH
· Real-Time Price · USD
10.90
0.00 (0.00%)
At close: Sep 04, 2025, 11:51 AM
0.00% (1D)
| Bid | 10.89 |
| Market Cap | 381.3M |
| Revenue (ttm) | 68.6M |
| Net Income (ttm) | 2.23M |
| EPS (ttm) | 0.09 |
| PE Ratio (ttm) | 121.11 |
| Forward PE | 19.46 |
| Analyst | Strong Buy |
| Ask | 10.9 |
| Volume | 89,714 |
| Avg. Volume (20D) | 760,740 |
| Open | 10.93 |
| Previous Close | 10.90 |
| Day's Range | 10.81 - 11.01 |
| 52-Week Range | 8.08 - 18.23 |
| Beta | 0.82 |
About DCTH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DCTH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DCTH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Delcath Systems Inc. is scheduled to release its earnings on
Nov 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+1.14%
Delcath Systems shares are trading higher after th...
Unlock content with
Pro Subscription
3 months ago
-6.32%
DCTH stock has given up its prior gain. Delcath Systems shares were trading higher after the company issued FY25 guidance and provided business updates.
4 weeks ago · fool.com
Delcath (DCTH) Q2 Revenue Jumps 210%Delcath (DCTH) Q2 Revenue Jumps 210%
4 weeks ago · businesswire.com
Delcath Systems Reports Second Quarter 2025 Results and Business HighlightsQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
